Advantage Alpha Capital Partners LP Takes Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Advantage Alpha Capital Partners LP bought a new stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 8,813 shares of the specialty pharmaceutical company’s stock, valued at approximately $341,000.

A number of other institutional investors have also added to or reduced their stakes in COLL. Gladius Capital Management LP bought a new position in shares of Collegium Pharmaceutical in the 2nd quarter valued at about $32,000. nVerses Capital LLC lifted its stake in Collegium Pharmaceutical by 1,600.0% in the 2nd quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company’s stock valued at $55,000 after purchasing an additional 1,600 shares during the last quarter. GAMMA Investing LLC grew its holdings in Collegium Pharmaceutical by 124.5% during the third quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock worth $55,000 after purchasing an additional 792 shares during the period. CWM LLC increased its position in Collegium Pharmaceutical by 97.5% during the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock worth $58,000 after buying an additional 736 shares during the last quarter. Finally, AXA S.A. bought a new stake in Collegium Pharmaceutical in the second quarter valued at approximately $209,000.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Needham & Company LLC reiterated a “hold” rating on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. HC Wainwright lifted their price objective on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, September 5th. Truist Financial increased their price objective on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Piper Sandler reaffirmed a “neutral” rating and set a $37.00 target price on shares of Collegium Pharmaceutical in a report on Friday, October 11th. Finally, StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, Collegium Pharmaceutical has a consensus rating of “Moderate Buy” and a consensus target price of $42.60.

Collegium Pharmaceutical Trading Up 1.3 %

Shares of Collegium Pharmaceutical stock opened at $31.19 on Wednesday. Collegium Pharmaceutical, Inc. has a 52-week low of $25.16 and a 52-week high of $42.29. The stock has a market cap of $1.01 billion, a PE ratio of 13.27 and a beta of 0.95. The firm has a 50-day moving average of $35.56 and a 200-day moving average of $34.68. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97.

Insider Buying and Selling at Collegium Pharmaceutical

In related news, EVP Thomas B. Smith sold 9,593 shares of the firm’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $36.62, for a total value of $351,295.66. Following the transaction, the executive vice president now owns 53,816 shares in the company, valued at approximately $1,970,741.92. This trade represents a 15.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Shirley R. Kuhlmann sold 19,248 shares of the company’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $38.30, for a total transaction of $737,198.40. Following the sale, the executive vice president now directly owns 120,161 shares of the company’s stock, valued at $4,602,166.30. This represents a 13.81 % decrease in their position. The disclosure for this sale can be found here. Insiders own 3.98% of the company’s stock.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.